Newsroom
March 2, 2026
A large, retrospective study conducted by scientists at the University of Texas at San Antonio (UT San Antonio) suggests that people taking glucagon-like peptide-1 (GLP-1) receptor agonists — medications that are widely prescribed for metabolic disease — have a significantly lower risk of developing colorectal cancer compared with those taking aspirin. “This is astounding to […]
January 20, 2026
San Antonio Report: GLP-1 drugs revolutionize obesity and diabetes care in San Antonio
January 9, 2026
San Antonio Report: Under new criteria, 3 in 4 U.S. adults are considered obese
November 26, 2025
EurekaAlert!: UT Health San Antonio leads $4 million study on glucagon hormone’s role in diabetes, obesity
November 26, 2025
KENS 5: UT Health San Antonio now has $4 million to launch a first-of-its-kind study on diabetes and obesity
November 11, 2025
The first-of-its-kind study will examine how glucagon contributes to insulin secretion, glucose regulation and energy balance in people with obesity who have or have not undergone bariatric surgery.
